Drug Eluting Coronary Stents to Account for Over Three-Fourths Market Share by 2028: Fact.MR Study

Coronary Stents

Fact.MR, a market research and competitive intelligence provider, has conducted a complete analysis on the global coronary stents market, which is projected to rise at a prolific CAGR of 12.9% over the forecast period (2021 to 2028).

Currently, millions of people around the world suffer from coronary artery disease. Angioplasty has become a common treatment option for those suffering from atherosclerosis and heart attacks, thanks to the use of local moderate sedatives. Coronary stents are small expandable metal meshes that are inserted into the coronary arteries during percutaneous coronary intervention treatment.

The market is being driven by technological advancements in stenting operations, which have resulted in a reduction in manual errors during surgery. This is projected to increase the number of cardiologists who use these products in both, developing and developed countries. Furthermore, the market is expected to rise over the coming years due to improved reimbursements for percutaneous coronary intervention procedures.

Technological advances in coronary stents, such as the invention of bifurcation stents and the use of biodegradable materials, have resulted in more effective and better CVD treatment outcomes.

Another factor projected to drive utilization of coronary stents throughout the forecast period is the growing preference for minimally invasive surgeries (MIS). Coronary stenting procedures have the advantage of having tiny incision wounds, which leads to increased patient satisfaction. These procedures also result in shorter hospital stays and faster recovery times.

Key Takeaways from Market Study

  • Global coronary stents market to reach valuation of US$ 25.7 Bn by 2028.
  • Drug eluting stents to account for 80% share of the global coronary stents market.
  • Market in North America holds share of 30%.

Stenting technological advancements in terms of material, construction, and coatings play a key role in improving stent effectiveness and expanding their application areas. Furthermore, introducing unique products into the market helps companies attain a competitive advantage and increase product adoption,” says a Fact.MR analyst

Winning Strategy

Manufacturers are forming joint ventures, strategic alliances, and partnerships to improve production capacity and market penetration. Primary methods such as technology releases, acquisitions, and R&D initiatives are being prioritized by market players. Key manufacturers have begun to make strategic decisions to engage in mergers and acquisitions in order to expand their product portfolio and brand share in the market.

For instance,

  • In 2021, Cardiovascular Systems Inc. established a collaboration with Chansu Vascular Technologies, LLC to produce drug-coated peripheral and coronary balloons for use in drug eluting stents.

Request Sample Report

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the global coronary stents market, presenting historical demand data (2017-2020) and forecast statistics for the period of 2021-2028.

The study divulges essential insights on the market on the basis of product (bare metal stents, drug eluting stents, and bio-absorbable stents), across five major regions of the world (North America, Europe, Asia Pacific, Latin America, and MEA).

Fact.MR’s Domain Knowledge in Healthcare

Our healthcare consulting team guides organizations at each step of their business strategy by helping you understand how the latest influencers account for operational and strategic transformation in the healthcare sector. Our expertise in recognizing the challenges and trends impacting the global healthcare industry provides indispensable insights and support – encasing a strategic perspective that helps you identify critical issues and devise appropriate solutions.

For more information, refer to our market research report or contact the PR author.